Palm Tocotrienol Supplement for Alcohol-Related Fatty Liver Disease Study
Tests a palm vitamin E supplement against placebo in adults with alcoholic fatty liver disease.
Plain-language title generated from the registry record
Registry title: The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)
Key facts
- Where
- Cheras, MalaysiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07466485, who can take part
Where in Malaysia
- Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun RazakCheras, MalaysiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universiti Kebangsaan Malaysia Medical Centre
- Trial code
- NCT07466485
- Record updated
- 29 April 2026
- Original description
This clinical study aims to explore the potential liver-protective effects of palm tocotrienol-rich fraction (a form of Vitamin E) in adults with alcoholic fatty liver disease (AFLD). A total of 26 participants aged 18 to 65 years with AFLD will be randomly assigned to receive either tocotrienol (200 mg twice daily) or a placebo for six months. Throughout the study, participants will undergo regular liver health assessments including blood tests, FibroScan, and FibroTest, alongside evaluations of oxidative stress and inflammation markers. The study aims to determine whether tocotrienol can help improve liver function and reduce alcohol-related liver damage. Findings from this trial may provide valuable evidence for future clinical studies and highlight the potential of Malaysian palm-based tocotrienol as a natural, supportive approach to liver health.Read full original descriptionShow less
The Effect of Palm Tocotrienol Rich Fraction on Alcoholic Fatty Liver Disease (AFLD): A Phase II Clinical Trial
This clinical study aims to explore the potential liver-protective effects of palm tocotrienol-rich fraction (a form of Vitamin E) in adults with alcoholic fatty liver disease (AFLD). A total of 26 participants aged 18 to 65 years with AFLD will be randomly assigned to receive either tocotrienol (200 mg twice daily) or a placebo for six months. Throughout the study, participants will undergo regular liver health assessments including blood tests, FibroScan, and FibroTest, alongside evaluations of oxidative stress and inflammation markers. The study aims to determine whether tocotrienol can help improve liver function and reduce alcohol-related liver damage. Findings from this trial may provide valuable evidence for future clinical studies and highlight the potential of Malaysian palm-based tocotrienol as a natural, supportive approach to liver health.
Inclusion: Patients with history of alcoholic use disorder with clinical and biochemical evidence of alcoholic steatohepatitis (AST:ALT >2.0, elevated GGT); Patients with Maddrey's discriminant function ≤ 32, and do not require the treatment of corticosteroid therapy or pentoxifylline; Patients aged 18 to 65; Patients who could comply with alcohol abstinence.
Exclusion: Patients with other concomitant liver diseases:; Hepatitis B; Hepatitis C; Non-alcoholic fatty liver disease (NAFLD); Autoimmune hepatitis (AIH); Hereditary hemochromatosis; Patients taking vitamin E, herbal supplements, or other investigational products within 90 days prior to the participation in the study; Patients who have been taken any medications that could affect the treatment: hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic acid, pentoxifylline, long-term use of NSAIDs, statins, neuroleptics, anticonvulsant medications, high-dose acetaminophen(>=2.5g/day); Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study; Severe alcoholic hepatitis defined as Maddrey's discriminant function >32; Patients who are obese (a BMI of 30 kg/ m2 or more) and with metabolic syndromes; Patients with bleeding disorders and who have been on anticoagulant or antiaggregant treatments; Patients who have been on corticosteroid therapy or pentoxifylline for alcoholic hepatitis; Patients who have pyridoxine allergy or history; Patients who are judged by investigator that participation of the study is difficult due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor, serious metabolic disease, severe renal disease, severe pulmonary disease, severe cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease and etc; Patients with hepatocellular carcinoma; Pregnant patients; Patients who are breastfeeding; Patients with Childs C liver cirrhosis; Patients who could not comply with alcohol abstinence; Patient who considered ineligible for participation in the study as Investigator's judgment.